Sean M Post

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Comprehensive investigation of CD8 + T cells in acute myeloid leukemia (AML) is essential for developing immunotherapeutic strategies beyond immune checkpoint blockade. Herein, we performed single-cell RNA profiling of CD8 + T cells from 3 healthy bone marrow donors and 23 newly diagnosed (NewlyDx) and 8 relapsed/refractory (RelRef) patients with AML. Cells coexpressing canonical exhaustion markers formed a cluster constituting + T cells. We identified two effector CD8 + T-cell subsets characterized by distinct cytokine and metabolic profiles that were differentially enriched in NewlyDx and RelRef patients. We refined a 25-gene CD8-derived signature correlating with therapy resistance, including genes associated with activation, chemoresistance, and terminal differentiation. Pseudotemporal trajectory analysis supported enrichment of a terminally differentiated state in CD8 + T cells with high CD8-derived signature expression at relapse or refractory disease. Higher expression of the 25-gene CD8 AML signature correlated with poorer outcomes in previously untreated patients with AML, suggesting that the bona fide state of CD8 + T cells and their degree of differentiation are clinically relevant. Immune clonotype tracking revealed more phenotypic transitions in CD8 clonotypes in NewlyDx than in RelRef patients. Furthermore, CD8 + T cells from RelRef patients had a higher degree of clonal hyperexpansion associated with terminal differentiation and higher CD8-derived signature expression. Clonotype-derived antigen prediction revealed that most previously unreported clonotypes were patient-specific, suggesting significant heterogeneity in AML immunogenicity. Thus, immunologic reconstitution in AML is likely to be most successful at earlier disease stages when CD8 + T cells are less differentiated and have greater capacity for clonotype transitions.

Year:

2025

Comprehensive investigation of CD8+ T cells in acute myeloid leukemia (AML) is essential for developing immunotherapeutic strategies beyond immune checkpoint blockade. Herein, we performed single-cell RNA profiling of CD8+ T cells from 3 healthy bone marrow donors and 23 newly diagnosed (NewlyDx) and 8 relapsed/refractory (RelRef) AML patients. Cells co-expressing canonical exhaustion markers formed a cluster constituting

Year:

2024

Acute myeloid leukemia (AML) is driven by numerous molecular events that contribute to disease progression. Herein, we identify hnRNP K overexpression as a recurrent abnormality in AML that negatively correlates with patient survival. Overexpression of hnRNP K in murine fetal liver cells results in altered self-renewal and differentiation potential. Further, murine transplantation models reveal that hnRNP K overexpression results in myeloproliferation in vivo. Mechanistic studies expose a direct functional relationship between hnRNP K and RUNX1—a master transcriptional regulator of hematopoiesis often dysregulated in leukemia. Molecular analyses show that overexpression of hnRNP K results in an enrichment of an alternatively spliced isoform of RUNX1 lacking exon 4. Our work establishes hnRNP K’s oncogenic potential in influencing myelogenesis through its regulation of RUNX1 splicing and subsequent transcriptional activity.

Year:

2022

Collaborators (14)

Michael Green

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Dinler Antunes

Assistant Professor of Computational Biology

University of Houston

UNITED STATES
View details

Hussein A. Abbas

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marina Konopleva

Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Andrew Futreal

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Natalia Baran

Leading attending

University Hospital of Bern

SWITZERLAND
View details

Gheath Alatrash

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Patrick Reville

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Fatima Zahra Jelloul

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Courtney D. DiNardo

University of Pennsylvania

UNITED STATES
View details

Arif Harmanci

Assistant Professor

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Jared Burks

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christopher Ly

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Naval G. Daver

Professor of Medicine

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details